Propranolol for Migraine Prevention
Propranolol is a first-line agent for migraine prevention, with a recommended dosing range of 80 to 240 mg daily, typically started at 80 mg once daily and titrated upward based on response. 1
Dosing Regimen
Starting and Maintenance Doses
- Initial dose: 80 mg once daily (using extended-release formulation) 2
- Usual effective dose: 120-160 mg once daily 2
- Maximum dose: Up to 240 mg daily for migraine prevention 1
- Titration: Increase gradually at 3-7 day intervals until optimal response is achieved 2
The FDA-approved dosing for migraine prophylaxis begins at 80 mg daily, with gradual increases to 160-240 mg once daily as the usual effective range 2. Evidence consistently demonstrates efficacy across this dosing spectrum 1.
Important Dosing Considerations
- Time to effect: Clinical benefit may take 2-3 months to fully manifest, so each dose level deserves an adequate trial before escalation 1
- Duration of trial: If no satisfactory response occurs within 4-6 weeks after reaching maximal dose, discontinue therapy 2
- Discontinuation: Taper gradually over several weeks rather than stopping abruptly to avoid rebound phenomena 1, 2
Indications for Preventive Therapy
Consider propranolol when patients meet any of these criteria 1:
- ≥2 migraine attacks per month producing disability lasting ≥3 days per month
- Contraindication to or failure of acute treatments
- Use of abortive medication >2 times per week (risk of medication overuse headache)
- Uncommon migraine conditions: hemiplegic migraine, prolonged aura, or migrainous infarction
Contraindications
Absolute Contraindications
- Asthma or severe COPD (β-blockers can cause bronchospasm)
- Second- or third-degree heart block
- Severe bradycardia (heart rate <50 bpm)
- Decompensated heart failure
- Cardiogenic shock
- Hypersensitivity to propranolol
Relative Contraindications (Use with Caution)
- Diabetes mellitus (may mask hypoglycemia symptoms)
- Peripheral vascular disease (can worsen claudication)
- Depression (β-blockers may exacerbate depressive symptoms) 1
- Pregnancy (Category C; discuss risks/benefits with patients of childbearing potential)
Efficacy Evidence
Propranolol demonstrates robust efficacy with high-quality evidence. Meta-analysis shows a 44% reduction in migraine activity using daily headache recordings 3. Multiple randomized controlled trials consistently support its effectiveness 1, and recent systematic reviews confirm propranolol as superior to placebo, reducing episodic migraine headaches by 1.5 headaches per month 4.
Propranolol is comparable in effectiveness to other first-line agents including topiramate, valproate, and amitriptyline 5. One trial suggests propranolol may be more efficacious than amitriptyline specifically for patients with migraine alone (rather than mixed migraine and tension-type headache) 1.
Common Adverse Effects
The most frequently reported side effects are 1:
- Fatigue
- Depression
- Nausea
- Dizziness
- Insomnia
These symptoms are generally well-tolerated and rarely cause treatment discontinuation in clinical trials 1. Lower doses (as low as 40-80 mg daily) can be effective in many patients and may minimize side effects 6.
Clinical Pearls
- β-blockers with intrinsic sympathomimetic activity (acebutolol, pindolol, oxprenolol) are ineffective for migraine prevention and should not be used 1
- Extended-release formulations are not mg-for-mg equivalent to immediate-release tablets; retitration may be necessary when switching 2
- Low-dose propranolol (40-80 mg daily) controls migraine in approximately 73% of patients, with only 30% requiring higher doses 6
- Propranolol can be combined with other preventive agents if monotherapy fails, though evidence for combination therapy is limited 7